Table 2.
First-line treatment of newly diagnosed multiple myeloma patients.
| MM t(11;14) (N = 96) | MM SR (N = 391) | MM HRCA (N = 104) | P value | |
|---|---|---|---|---|
| Number of treatment lines (median, range) | 2 (0–8) | 2 (0–14) | 2 (1–8) | No statistically significant differences were observed |
| Conventional treatment induction scheme | ||||
| • Conventional treatment in the first line | 44.4% (40 of 90) | 34.4% (128 of 372) | 36.4% (36 of 99) | |
| • Conventional chemotherapy (CyP, MP) | 22.2% (20 of 90) | 14.4% (54 of 372) | 13.2% (13 of 99) | |
| • Polychemotherapy (VBCMP, VBAD, VAD) | 22.2% (20 of 90) | 20.0% (74 of 372) | 23.2% (23 of 99) | |
| Novel agents – based induction schemes | ||||
| • Novel agents in the first line | 55.6% (50 of 90) | 65.6% (244 of 372) | 63.6% (63 of 99) | |
| • 1 Novel agent in the first line | 42.2% (38 of 90) | 43.8% (163 of 372) | 39.4% (39 of 99 | |
| • ≥2 novel agents in the first line | 13.4% (12 of 90) | 21.8% (81 of 372) | 24.2% (24 of 99) | |
| • PI-based regimens (VD, VMP, VCD, PAD…) | 38.9% (35 of 90) | 38.7% (144 of 372) | 35.4% (35 of 99) | |
| • IMID-based regimens (TD, TCD, TAD, Rd..) | 3.3% (3 of 90) | 5.6% (21 of 372) | 4.0% (4 of 99) | |
| • PI plus IMID (VTD, VRD…) | 11.1% (10 of 90) | 18.5% (69 of 372) | 19.2% (19 of 99) | |
| • Anti-CD38-based regimens | 2.2% (2 of 90) | 2.7% (10 of 372) | 5.1% (5 of 99) | |
| ASCT | 43.2% (41 of 95) | 44.8% (175 of 391) | 51.0% (53 of 104) | |
MM multiple myeloma, HRCA high-risk chromosomal abnormalities, PI proteasome inhibitor, IMID immunomodulator, CyP cyclophosphamide and prednisone, MP melphalan prednisone, VBCMP vincristine, carmustine, cyclophosphamide, melphalan, and prednisone, VBAD vincristine, bleomycin, adriamycin, and dexamethasone, VAD vincristine, adriamycin, and dexamethasone, VD bortezomib and dexamethasone, VMP bortezomib, melphalan, and dexamethasone, VCD bortezomib, cyclophosphamide, and dexamethasone, PAD bortezomib, adriamycin, and dexamethasone TD thalidomid and dexamethasone, TCD thalidomide, cyclophosphamide, and dexamethasone, TAD thalidomide, adriamycin, and dexamethasone, Rd lenalidomide and dexamethasone, VTD bortezomib, thalidomide, and dexamethasone, VRD bortezomib, lenalidomide, and dexamethasone, ASCT autologous stem cell transplantation.